ArticleGynecologic oncology2017

SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2/Neu expression.

Gulden Menderes et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.